vs

Side-by-side financial comparison of R F INDUSTRIES LTD (RFIL) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

R F INDUSTRIES LTD is the larger business by last-quarter revenue ($22.7M vs $12.5M, roughly 1.8× Avidity Biosciences, Inc.). R F INDUSTRIES LTD runs the higher net margin — 0.8% vs -1398.3%, a 1399.1% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 22.9%). R F INDUSTRIES LTD produced more free cash flow last quarter ($2.0M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 29.8%).

Tootsie Roll Industries is an American manufacturer of confectionery based in Chicago, Illinois. Its best-known products include the namesake Tootsie Rolls and Tootsie Pops. Tootsie Roll Industries currently markets its brands internationally in Canada, Mexico, and over 75 other countries.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

RFIL vs RNA — Head-to-Head

Bigger by revenue
RFIL
RFIL
1.8× larger
RFIL
$22.7M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+411.1% gap
RNA
434.0%
22.9%
RFIL
Higher net margin
RFIL
RFIL
1399.1% more per $
RFIL
0.8%
-1398.3%
RNA
More free cash flow
RFIL
RFIL
$158.9M more FCF
RFIL
$2.0M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
29.8%
RFIL

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
RFIL
RFIL
RNA
RNA
Revenue
$22.7M
$12.5M
Net Profit
$173.0K
$-174.4M
Gross Margin
36.8%
Operating Margin
4.0%
-1513.5%
Net Margin
0.8%
-1398.3%
Revenue YoY
22.9%
434.0%
Net Profit YoY
172.7%
-117.0%
EPS (diluted)
$0.01
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RFIL
RFIL
RNA
RNA
Q4 25
$22.7M
Q3 25
$19.8M
$12.5M
Q2 25
$18.9M
$3.8M
Q1 25
$19.2M
$1.6M
Q4 24
$18.5M
$3.0M
Q3 24
$16.8M
$2.3M
Q2 24
$16.1M
$2.0M
Q1 24
$13.5M
$3.5M
Net Profit
RFIL
RFIL
RNA
RNA
Q4 25
$173.0K
Q3 25
$392.0K
$-174.4M
Q2 25
$-245.0K
$-157.3M
Q1 25
$-245.0K
$-115.8M
Q4 24
$-238.0K
$-102.3M
Q3 24
$-705.0K
$-80.4M
Q2 24
$-4.3M
$-70.8M
Q1 24
$-1.4M
$-68.9M
Gross Margin
RFIL
RFIL
RNA
RNA
Q4 25
36.8%
Q3 25
34.0%
Q2 25
31.5%
Q1 25
29.8%
Q4 24
31.3%
Q3 24
29.5%
Q2 24
29.9%
Q1 24
24.5%
Operating Margin
RFIL
RFIL
RNA
RNA
Q4 25
4.0%
Q3 25
3.6%
-1513.5%
Q2 25
0.6%
-4448.7%
Q1 25
0.3%
-8360.9%
Q4 24
0.5%
-4069.6%
Q3 24
-2.5%
-4200.9%
Q2 24
-2.6%
-4040.4%
Q1 24
-15.5%
-2178.6%
Net Margin
RFIL
RFIL
RNA
RNA
Q4 25
0.8%
Q3 25
2.0%
-1398.3%
Q2 25
-1.3%
-4089.3%
Q1 25
-1.3%
-7360.0%
Q4 24
-1.3%
-3439.5%
Q3 24
-4.2%
-3441.7%
Q2 24
-26.7%
-3461.8%
Q1 24
-10.1%
-1943.4%
EPS (diluted)
RFIL
RFIL
RNA
RNA
Q4 25
$0.01
Q3 25
$0.04
$-1.27
Q2 25
$-0.02
$-1.21
Q1 25
$-0.02
$-0.90
Q4 24
$-0.02
$-0.80
Q3 24
$-0.07
$-0.65
Q2 24
$-0.41
$-0.65
Q1 24
$-0.13
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RFIL
RFIL
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$5.1M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$35.2M
$1.9B
Total Assets
$73.0M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RFIL
RFIL
RNA
RNA
Q4 25
$5.1M
Q3 25
$3.0M
$350.2M
Q2 25
$3.6M
$243.9M
Q1 25
$1.3M
$254.2M
Q4 24
$839.0K
$219.9M
Q3 24
$1.8M
$370.2M
Q2 24
$1.4M
$575.8M
Q1 24
$4.5M
$471.4M
Stockholders' Equity
RFIL
RFIL
RNA
RNA
Q4 25
$35.2M
Q3 25
$34.8M
$1.9B
Q2 25
$34.2M
$1.2B
Q1 25
$34.2M
$1.3B
Q4 24
$34.1M
$1.4B
Q3 24
$34.1M
$1.5B
Q2 24
$34.6M
$1.2B
Q1 24
$38.7M
$830.9M
Total Assets
RFIL
RFIL
RNA
RNA
Q4 25
$73.0M
Q3 25
$73.2M
$2.1B
Q2 25
$72.7M
$1.4B
Q1 25
$70.4M
$1.5B
Q4 24
$71.0M
$1.6B
Q3 24
$71.9M
$1.6B
Q2 24
$72.8M
$1.3B
Q1 24
$79.1M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RFIL
RFIL
RNA
RNA
Operating Cash FlowLast quarter
$2.1M
$-156.2M
Free Cash FlowOCF − Capex
$2.0M
$-156.9M
FCF MarginFCF / Revenue
9.0%
-1257.6%
Capex IntensityCapex / Revenue
0.3%
5.7%
Cash ConversionOCF / Net Profit
12.13×
TTM Free Cash FlowTrailing 4 quarters
$4.3M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RFIL
RFIL
RNA
RNA
Q4 25
$2.1M
Q3 25
$-311.0K
$-156.2M
Q2 25
$2.2M
$-199.7M
Q1 25
$601.0K
$-124.8M
Q4 24
$-244.0K
$-99.9M
Q3 24
$2.4M
$-65.6M
Q2 24
$197.0K
$-65.0M
Q1 24
$840.0K
$-70.4M
Free Cash Flow
RFIL
RFIL
RNA
RNA
Q4 25
$2.0M
Q3 25
$-419.0K
$-156.9M
Q2 25
$2.2M
$-203.0M
Q1 25
$574.0K
$-128.6M
Q4 24
$-418.0K
$-103.8M
Q3 24
$2.1M
$-67.3M
Q2 24
$28.0K
$-65.5M
Q1 24
$697.0K
$-71.3M
FCF Margin
RFIL
RFIL
RNA
RNA
Q4 25
9.0%
Q3 25
-2.1%
-1257.6%
Q2 25
11.4%
-5277.1%
Q1 25
3.0%
-8174.3%
Q4 24
-2.3%
-3491.0%
Q3 24
12.6%
-2881.8%
Q2 24
0.2%
-3204.6%
Q1 24
5.2%
-2012.3%
Capex Intensity
RFIL
RFIL
RNA
RNA
Q4 25
0.3%
Q3 25
0.5%
5.7%
Q2 25
0.2%
86.9%
Q1 25
0.1%
238.6%
Q4 24
0.9%
131.7%
Q3 24
1.5%
72.9%
Q2 24
1.0%
26.0%
Q1 24
1.1%
25.8%
Cash Conversion
RFIL
RFIL
RNA
RNA
Q4 25
12.13×
Q3 25
-0.79×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RFIL
RFIL

US$20.9M92%
Non Us$1.8M8%

RNA
RNA

Segment breakdown not available.

Related Comparisons